Novartis AG Common Stock (NVS)

When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).

10 Smart Dividend Stocks for the Rest of the Year

By James Brumley, InvestorPlace Feature Writer Jun 11, 2019

Ford, Verizon and AbbVie are just a trio of the top dividend stocks to buy for the remainder of 2019, particularly if the broad market hits turbulence.

New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

By William White, InvestorPlace Writer Jun 7, 2019

There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.

Continued Smart M&A Moves Will Help Canopy Stock Break Out

By Luce Emerson, InvestorPlace Contributor Jun 5, 2019

Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.

4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS

By Bret Kenwell, InvestorPlace Contributor May 24, 2019

Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.

How and Why Tilray Stock Is a Buy Here

By Chris Tyler, InvestorPlace Contributor May 24, 2019

Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.

3 Ways to Buy Into the Marijuana Boom Without the Risk

By Aaron Levitt, InvestorPlace Contributor May 20, 2019

Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.

Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock

By Luce Emerson, InvestorPlace Contributor May 17, 2019

After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.

7 Strong Buy Stocks That Tick All the Boxes

By Harriet Lefton, Writer, TipRanks May 6, 2019

With the bull market continuing at a breakneck pace, you want to look for strong buy stocks with plenty of support in case of pullback.

5 Biotech Stocks for a Long-Lived Portfolio

By Chris Lau, InvestorPlace Contributor Apr 30, 2019

Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.

Here’s the Real Problem with Altria Overpaying for CRON Stock

By Luce Emerson, InvestorPlace Contributor Apr 11, 2019

Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.

Novartis AG Common Stock (NVS)

The Medicines Company News: MDCO Stock Rockets 22% on Novartis Deal

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline

10 Stocks to Short Now — Before They Plummet

10 Great Biotech Stocks to Buy in Q4

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Novartis AG Common Stock (NVS)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

NVS Stock Predictions, Articles, and Novartis AG Common Stock News

Subscriber Sign in